Online inquiry

IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15860MR)

This product GTTS-WQ15860MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ15860MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7421MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GA201
GTTS-WQ14356MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG7716
GTTS-WQ14642MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ12711MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ7582MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA G-CSF
GTTS-WQ2087MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AIN457
GTTS-WQ11653MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ11433MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-8897
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW